The Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting - X4 Pharmaceuticals

The Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

The Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

November 2018

X4P-001, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Tumor Inflammatory Status in the Microenvironment of Melanoma

© 2023 X4 Pharmaceuticals, Inc. All rights reserved. Terms of Use | Privacy Policy